These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The eosinophilia-myalgia syndrome: opportunities realized and missed. Hertzman PA J Rheumatol; 1996 Oct; 23(10):1679-81. PubMed ID: 8895138 [No Abstract] [Full Text] [Related]
3. [Current aspects in discussion of eosinophilia-myalgia syndrome]. Zipp F; Demisch L Nervenarzt; 1992 Apr; 63(4):249-53. PubMed ID: 1594093 [No Abstract] [Full Text] [Related]
4. Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead. Sidransky H Mod Pathol; 1994 Sep; 7(7):806-10. PubMed ID: 7824518 [TBL] [Abstract][Full Text] [Related]
6. Eosinophilia-myalgia syndrome: coming to grips with a new illness. Kilbourne EM Epidemiol Rev; 1992; 14():16-36. PubMed ID: 1289111 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. Sternberg EM Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284 [TBL] [Abstract][Full Text] [Related]
9. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. Shapiro S J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181 [TBL] [Abstract][Full Text] [Related]
10. Eosinophilia-myalgia syndrome not associated with L-tryptophan. Patmas MA N J Med; 1992 Apr; 89(4):285-6. PubMed ID: 1603435 [TBL] [Abstract][Full Text] [Related]
11. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Varga J; Uitto J; Jimenez SA Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618 [TBL] [Abstract][Full Text] [Related]
12. [Eosinophilia-myalgia: new syndrome]. SzechiĆski J; Borysewicz K Postepy Hig Med Dosw; 1992; 46(3):319-25. PubMed ID: 1369828 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York. Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862 [TBL] [Abstract][Full Text] [Related]
14. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395 [No Abstract] [Full Text] [Related]
15. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. Kilbourne EM; Philen RM; Kamb ML; Falk H J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184 [TBL] [Abstract][Full Text] [Related]
16. The eosinophilia-myalgia syndrome: lessons from Germany. Mayeno AN; Gleich GJ Mayo Clin Proc; 1994 Jul; 69(7):702-4. PubMed ID: 8015338 [No Abstract] [Full Text] [Related]
17. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil]. Maitani T; Saitoh H Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617 [No Abstract] [Full Text] [Related]